For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Olympus: Strong Overseas Sales of Medical Endoscopes Support Growth
June 10, 2002
- Tanabe: Sales Decline Due to Transfer of Diagnostics to Eiken
June 10, 2002
- Toho Pharm: Profits Down Despite 16.8% Increase in Sales
June 10, 2002
- Cost Calculation Method Employed for Elastase, Acetylcysteine
June 10, 2002
- Ono: Opalmon, Onon Drive Sales, Profits
June 10, 2002
- Vital-Net: Becomes No. 1 Drug Wholesaler in Tohoku Region
June 10, 2002
- OTC NEWS IN BRIEF
June 10, 2002
- Tsumura: Net Profits for 1st Time in 5 Years
June 10, 2002
- BULLETIN
June 10, 2002
- REGULATORY NEWS IN BRIEF
June 10, 2002
- Kaken: Sales Up 4.2%, Effects of Competitors on Artz Are Minimal
June 10, 2002
- Taisho Licenses mGluR Agonists to Merck
June 10, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 10, 2002
- SSP: Sales, Profits Plummet Due to Slump in Self-medication
June 10, 2002
- Chugai, Biostar, Jicchuken Create Post-genomic Research Company in Singapore
June 10, 2002
- Late PII Results on Humanized Antibody MRA Reported: Chugai
June 10, 2002
- Mochida: Sales Down Due to Decline in Mainstays
June 10, 2002
- Sosei Introduces Brain Tumor Treatment from KS Biomedix of the UK
June 10, 2002
- Fulminant Type 1 Diabetes Can Be Fatal if not Treated Immediately
June 10, 2002
- Kyorin: New Record-high Consolidated Sales Reported
June 10, 2002
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…